We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Bladder Cancer

Journal Scan / Review · December 16, 2020

Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder

European Urology Oncology

 

Additional Info

European Urology Oncology
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder
Eur Urol Oncol 2020 Nov 08;[EPub Ahead of Print], M Rouanne, DF Bajorin, R Hannan, MD Galsky, SB Williams, A Necchi, P Sharma, T Powles

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading